$NAMS

NewAmsterdam Pharma Company NV

$NAMS

NewAmsterdam Pharma Company NV

Past 12mo:2mentions2voices

All voices1 call since Jul 2026show all

Loading price chart…

Recent calls

1 call

@investmentguru_Jul 5, 2026 · 11:36 AM

$NAMS NewAmsterdam Pharma is a clinical-stage cardiometabolic play centered on obicetrapib, an oral once-daily CETP inhibitor designed to lower LDL-C as an add-on to statin therapy, and the stock has pulled back to around $29.83 (market cap ~$3.49B) after peaking near $42.21 over the past year, largely on broader biotech volatility rather than any deterioration in the underlying story — Q1 2026 results actually beat expectations with a narrower loss and stronger revenue, and Wall Street sentiment remains firmly bullish, with 13 analysts on Buy, none on Sell, and an average 12-month price target near $50, implying meaningful upside from current levels if the thesis plays out. The next catalyst on deck is the Aug 12, 2026 earnings report, alongside continued data flow from the pivotal PREVAIL cardiovascular outcomes trial, either of which could reignite momentum given the current gap between price and where the Street sees fair value. Not financial advice.

Open on X